Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a relapsed or treatment-resistant CD19-positive B-cell leukemia or lymphoma, confirmed by a laboratory tissue or cell sample, and who have already received a commercially approved CAR-T cell therapy for this condition.
• People who are enrolling between 28 and 56 days after receiving their CAR-T cell infusion.
• People who are 18 years of age or older at the time of enrollment.
• People who are able to swallow pills or tablets.
• People whose general physical functioning is rated at 50% or above on a standard medical performance scale (confirm with trial site).
• People whose blood counts meet certain minimum levels for white blood cells (neutrophils) and platelets, as measured by a blood test (confirm with trial site for exact thresholds).
• People whose liver function blood test results fall within acceptable ranges set by the trial (confirm with trial site).
• People whose blood protein (albumin) and kidney function levels meet the minimum levels required by the trial (confirm with trial site).
• People who are sexually active and capable of becoming pregnant, or males, who agree to take part in a specific safety program related to the study drug pomalidomide (called a REMS program).
• People who agree not to donate blood during treatment with pomalidomide and for at least 4 weeks after stopping the drug.

Who may not be able to join:

• People whose cancer is currently progressing or not responding to treatment.
• People who are currently experiencing moderate or severe graft-versus-host disease (a reaction sometimes seen after transplants), or moderate to severe side effects from CAR-T therapy such as cytokine release syndrome or immune-related neurological effects (confirm with trial site for grade definitions).
• People currently taking moderate-to-high doses of steroid medications (such as methylprednisolone or equivalent).
• People currently taking certain medications known to interact with pomalidomide, including ciprofloxacin, omeprazole, cimetidine, estrogen, or fluvoxamine.
• People who currently smoke cigarettes.
• People who have received any new cancer treatment — including chemotherapy, targeted biological therapies, or immunotherapy checkpoint drugs — within the 28 days before enrolling in the study.
• People who have received radiation therapy within the 28 days before enrolling.
• People who have had a stem cell transplant after their most recent CAR-T therapy.
• People who have a known allergy or sensitivity to pomalidomide or similar compounds.
• People with infections that are not under control, or who have had a confirmed blood or fungal infection requiring antibiotic treatment in the 72 hours before enrollment.
• People with severe (grade 4) organ toxicity affecting the gut, liver, lungs, kidneys, or heart, or people who require dialysis.
• People with certain inherited conditions that affect bone marrow function, such as Fanconi anemia, severe congenital neutropenia, or Shwachman syndrome (note: people with Down syndrome are not excluded).
• People who have had a blood clot in an artery or vein, a pulmonary embolism, stroke, or heart attack within the 3 months before enrolling.
• People who are currently pregnant or breastfeeding (breastfeeding would need to stop during treatment and for at least 4 weeks after the study drug is discontinued).
• People who have tested positive for HIV within 8 weeks of screening.

Important: Always verify eligibility with the trial site directly before applying.